GLOBAL PHARMA INDUSTRY

BY

DHANIL FRANCIL

Analysing the changes in global pharmaceutical industry

Introduction

The path of drug industriesGovernment intervention on drug marketUn pleasant environment in marketMarket strategiesPressures from different industries all over the

worldNew tactics to boost up the industryRecommendation

PESTELP- POLITICALE-ECONOMICALS-SOCIALT-TECHNOLOGICALE-ENVIRONMENTALL-LEGAL

POLITICAL

Political monitoring- FDA(Food and Drug Administration put a new barrier over the new agencies.

Market approval- Government put more hurdles to over come the market ban.

Political target- Pharmaceutical industry a easy target politically to control rising health care expenditure.

Government Attitude- Many governments imposed price and Start compensating companies for an expense.

Controls on suppliers-• Negotiated Prices• Average pricing• Reference pricing• Positive and negative listsConstraints on wholesalers & pharmacists• Imposed price cuts• Controls to influence demand-• Patient co-payments• Treatment guidelines• Fixed budgets & Parallel imports

EconomicalGrowth- • $80 billion in 2008 with projected sales of

three times of that.• Companies invested in biologics incurred a

rapid growth.Investment-• Invested in biologics.• Invested in the R&D module.Opportunities-• Molecular biology & genetic engineering

Marketing structure-

Manufacturing goods

R&D

Administration

Sales & marketing

SocialHealth consciousness & welfare-• FDA is adminisrating it on the basis of purity,

stability, safety, efficacy and tolerability• It has a strict eye over the pattern expiry.Competitive attitude-• Align sales and marketing business processes• Realign and refocus sales efforts as needed• Redefine Customer Engagement Models

Advertising-• DTC advertising through television makes a

profitable high profile for the industry.• Through sales representatives.• Through physician guarantee.Consumer behaviour -• Price sensitivity• Trust to the medicine or company • Experience with the brand keeps there

relation with that particular product or its producer.

TechnologicalFocus on technology-• American based companies concentrate more

in R&D process.• The Advancement of technology is still a high

secret as there is a chance for there competitors to eat there years of hard work.

R&D activity-• The pipeline starts with new drug discoveries

and it is important to assess companies' ability to discover new drugs as well as drugs that are currently in the pipeline.

Pipeline

• It takes 15 years for a pipeline to completeDrug discovery Pre clinical

Clinical trials

FDA reviews

Market

EnvironmentalRisk-• Allegra lost US market 84%.• Its un usual since many countries subjet to

monospony.• Government price controls created a parallel

trade.• Wide disparity in prices.• company has strong pipe line but weak sales

and marketing strategies.

Off label-• Eli lilly paid a fine of $1.4bn for off label

promotion of the drug Zyprexa.• Lack of trust over FDA.• Company accused of putting profit before

patients safety.• Turning necessity to opportunity

Legal

Governing & inspecting.• Processing of pharmaceuticals.• Assembling of medical devices.• New establishment.• Relocation.• Expansion.• Reopening. • Regional routine inspections

Medical organizations-• NICE- National institute for clinical

effectiveness, it operates in Uk.• MCO- Managed care organization it operates

in United States health Care Markets.• FDA- Food and drug Administration.

The key forces are• The unmet needs of medicines for diseases as

it take 15 years to establish a medicine.• American companies were driven off as more

companies were started In eastern continents.• The US global supply was reduced because of

Certain profit motto companies with in them(Eli Lilly).

• Big pharma and bio-tech sectors met with toughest out look because of the vast R&D period.

Conclusion

I conclude that the pharmaceutical industry is too slow in R&D process. As the marketing structure shows R&D spends lots of money and time, a better fast way of research & development, ie a new model of drug development method will help. The industry which produce fast, reliable and trustable medicine will hold the pharmaceutical environment.

Thank you